7
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T3595 |
Resmetirom
VIA-3196,MGL3196 |
Thyroid hormone receptor(THR) | Endocrinology/Hormones |
Resmetirom (VIA-3196) 是一种高度选择性的THR-β激动剂(EC50:0.21 μM)。 | |||
T5313 |
Sobetirome
IACS-010759,QRX-431 |
Thyroid hormone receptor(THR) | Endocrinology/Hormones |
Sobetirome (IACS-010759) 是一种甲状腺激素受体 β (TRβ) 激动剂,能够选择性的结合到TRβ-1(EC50:0.16 μM)。 | |||
T79089 | THR-β modulator-1 | ||
THR-β modulator-1(compound 1a)是高效的甲状腺激素受体β(THR-β)调节剂,适用于甲状腺激素受体相关疾病的研究。 | |||
T11954 |
MB-07344
|
Others | Others |
MB-07344 has additive cholesterol lowering activity in combination with Atorvastatin in rabbits, dogs and monkeys. MB-07344 is a potent thyroid hormone receptor (TR)-β agonist with a Ki of 2.17 nM. | |||
T63876 |
TRβ agonist 1
|
||
TRβ agonist 1 为一种选择性且对突变敏感的甲状腺激素受体 β (TRβ) 激动剂,其EC50值为21 nM。该化合物适用于血脂异常、非酒精性脂肪性肝炎 (NASH) 与甲状腺激素抵抗 (RTH) 研究。 | |||
T11954L |
MB-07344 sodium
|
Others | Others |
MB-07344 sodium has additive cholesterol lowering activity in combination with Atorvastatin in rabbits, dogs and monkeys. MB-07344 sodium is a potent thyroid hormone receptor (TR)-β agonist with a Ki of 2.17 nM. | |||
T74785 | THR-β agonist 6 | ||
THR-β agonist 6 是一种口服活性的选择性甲状腺激素受体 β(THR-β)激动剂,其对THR-β和THR-α的EC50值分别为0.03 μM和0.22 μM,展示出93:1显著的肝血清比,在小鼠中证明其优异性。此化合物在非酒精性脂肪性肝炎(NASH)研究中显示出潜在应用价值。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-06821 |
THRB Protein, Human, Recombinant (His)
THRB1,GRTH,THR1,ERBA2,C-ERBA-2,THRB2,thyroid ho... |
Human | E. coli |
Thyroid hormone receptor beta (THRB), also known as TRbeta and NR1A2, belongs to the nuclear hormone receptor family. Featuring an N-terminal transactivation domain, a central DNA-binding domain, and a hormone/ligand-binding domain, THRB isoform 1/2 expression localizes predominately to the liver and pituitary, respectively. THRB regulates the feedback of T3-dependent thyrotropin-stimulating hormone (TSH) transcription in the pituitary by binding to thyroid hormone (TH) response elements present... |